We primarily used therapy duration and changes in PSA level to define clinical response.10 We confirmed soft tissue progression using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)11 criteria and bone disease progression using protocol by Prostate Cancer Working Group 212 criteria (Appendix). The gene discussed is KLK3; the disease is Familial prostate cancer.